VEGFA and diabetic retinopathy: Limitations of the analysis include its retrospective design, the imputation of missing data (last-observation-carried-forward method) and the absence of information on other factors that might influence DMO progression and response to anti-VEGF therapy, such as disease duration, subtype and morphologic pattern, severity of diabetic retinopathy and macular ischaemia and level of glycaemic control [28, 37–40].